Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis - Wikidata - awgldk - TriplyDB

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

http://www.wikidata.org/entity/Q36669451

about

Location of intra- and extracellular M. tuberculosis populations in lungs of mice and guinea pigs during disease progression and after drug treatment Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum Bactericidal activity of an imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection model Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis The Role of Adherence and Retreatment in De Novo Emergence of MDR-TB In silico evaluation and exploration of antibiotic tuberculosis treatment regimens A multi-scale approach to designing therapeutics for tuberculosis A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists.Understanding pharmacokinetics to improve tuberculosis treatment outcome.Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses?PA-824 exhibits time-dependent activity in a murine model of tuberculosis.In vitro pharmacokinetic/pharmacodynamic models in anti-infective drug development: focus on TB Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients.Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models Reply to "breakpoints and drug exposure are inevitably closely linked"Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs.Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis.Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.Computational pharmacokinetics/pharmacodynamics of rifampin in a mouse tuberculosis infection model Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping.A Flow Cytometry Method for Rapidly Assessing Mycobacterium tuberculosis Responses to Antibiotics with Different Modes of Action The chemotherapy of tuberculosis: past, present and future.Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs.Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners.A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.The medical and surgical treatment of drug-resistant tuberculosis.An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.Therapeutic drug monitoring in the treatment of tuberculosis: an update.Macrophage-specific targeting of isoniazid through mannosylated gelatin microspheres.Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.

P2860

Q28477456-FCB625A2-B8B7-4A0E-83D5-564640E5EDC9 Q28478890-06CD742E-A5D4-4C5F-849A-A81C59D5FF02 Q28539383-F2B89A85-A745-4710-9932-ACEA1559003D Q28542435-C863AE14-D8BD-4D48-9066-C607B1425E6B Q28550707-EFEBE9D0-4A33-41A5-B2E4-6BD119E7FE3A Q28607283-3B9C9105-7D34-4182-B697-FBED0AA8BF7D Q28647309-1278E375-EFC0-4E5B-A757-46C130CB24B1 Q28649754-D8BE58E6-AC60-4E7D-A5C3-D152E92741E5 Q30383012-210BC32E-CEFC-4C75-AEDA-36C1C2246DF2 Q30411703-13EA0CFF-51CC-4DC4-95A4-42980A8A9458 Q33723589-8377B018-3BC4-409B-96EE-69412E0764B2 Q33770163-45AB8EC9-04E7-4582-B719-2AD896403486 Q34483632-F960CAC7-5932-4514-A5E5-5835D56AAD78 Q34591451-D6A9D203-27EE-4A82-80E2-527AD7A436E4 Q34597564-B61EAC7B-5713-4C56-97CF-78F015916C71 Q34729493-54ABEA32-8DE6-4DBD-81E6-296300E67CDC Q35037392-BCF4DDC2-5A67-4E42-8C2B-98373E2363CF Q35106037-AB9B9C55-8AC5-48F1-9E0E-29641B0E255A Q35167178-25526E6F-9E38-4C5C-B26E-86B363803C5C Q35242238-79D3975A-D24B-4AD6-B940-F2C38E1DFE87 Q35636012-7B794E95-65BE-4FD1-B470-6A3CBD72C42D Q35746184-EAEDCDDC-8526-47C3-9539-B86A6B9F730B Q35806445-D48B83A8-1CD0-4F9C-ACA2-19CB7AEF95DA Q35864589-2CA4F767-4184-4241-AA55-8E3E2EBBE908 Q35960852-59E96C8C-6EFD-4282-A3B3-582A43006313 Q36379388-6A453DFB-0E21-4AAB-8CE1-1FBBE00EB859 Q36809405-75F080F5-0317-4361-8B97-AF4AE4BEC8F8 Q36870723-A76E4CB7-41A6-4B17-AA14-FC8FA1462798 Q36994443-72B6C9FB-CA02-4439-8A35-85508E943A35 Q37023216-0037C4C0-4FFF-48BA-AEDE-C25C0575152D Q37076746-92EE58AA-FDD6-4E27-AB31-015C13485FB0 Q37274688-991F194F-AC59-4211-AB2E-AC3281560C99 Q37335803-16C0D1AC-8260-4441-AC78-EBFDBF62D4A6 Q37441394-50C1F414-B444-419F-BD4D-4F53DCB2F203 Q37629518-1B214FEE-B398-48ED-BAAB-BC23474F31D1 Q37799461-DFB17EBE-48F6-41CA-8BE3-AF6EEDDA4188 Q38093135-231F4B20-8A4A-43CA-A57E-741D1ABD29EE Q38213320-538A2386-DA7D-4A99-B1AB-CF5E1E133B20 Q38311993-205E1837-F783-47C3-B226-C936EBDE3373 Q38502298-831E04A3-C0CC-42EA-8EFB-991D323D655D

P2860

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

http://www.wikidata.org/entity/Q36669451

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

@ast

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

@en

type

label

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

@ast

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

@en

prefLabel

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

@ast

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

@en

P1433

Q36669451-1259EB88-1815-4D0A-81B9-3AB5BA5789B1

P1476

Q36669451-889BA13F-5263-4FF4-AC3F-3C2E3D1BB80C

P2093

Q36669451-1A5A8F71-340F-42D3-AAE2-7C003B251219

Q36669451-389CD966-6818-410E-A391-886B961D4E1B

Q36669451-58193164-E2FD-4D12-B4B8-C0E05C90E24A

Q36669451-5C039E34-F26F-424F-9D28-57B41C7BB6B7

Q36669451-70DD8F37-288F-4922-A695-8AD61B42819C

Q36669451-919A1F29-5A54-45B3-A25B-2CE727465A94

Q36669451-91F84CCB-2BFA-4902-A4AD-01832E6F63A4

Q36669451-B319AA4D-1417-4007-BB65-37AA424241C0

Q36669451-D7E591CD-B5DB-49FC-B059-880DDF162BD0

Q36669451-EC05CCD2-C0CF-4347-BAC8-F99DB0638FD5

P2860

Q36669451-0CC1E745-350A-44D4-B948-AB49E420A863

Q36669451-20A542CF-C80A-4CFA-A096-CEE197356086

Q36669451-254737AC-4F29-4738-9A06-4483857A17AD

Q36669451-31C2D7D3-DE80-40DE-BC9B-B72FAEE2D9C8

Q36669451-3EC2D37E-2E5B-454F-B519-71B61582B3D4

Q36669451-43656709-8EB9-42CD-95F3-1CD3F69BFEAE

Q36669451-44AA1482-5B6D-4641-A1DA-02203CEC20ED

Q36669451-47F7B2CE-387A-42B1-9D9B-37BECF63D44C

Q36669451-64002D7B-8728-4024-8436-1ACEF4381EAA

Q36669451-79864A32-977A-4F87-8F18-D794A751D70E

P304

Q36669451-BD58674A-6445-4ED4-B8B9-1CAD198BBF05

P31

Q36669451-22F5D3AC-38E5-4F16-991D-DB8030E9D638

P356

Q36669451-A2A9F681-DC7B-4050-9939-CF0B0306EF71

P407

Q36669451-82B22D4B-2129-420C-9DA0-FDD4A07E6035

P433

Q36669451-5993831F-FFF4-453A-B2E6-F6395DB6BC5D

P478

Q36669451-CFFA9BA9-79B6-4930-9871-1FB7AB5924DC

P577

Q36669451-63CAFBD5-0AB8-4B4B-883E-2776734E1004

P698

Q36669451-A7AD8AAB-3CA1-41F5-9E68-3DE3753AAC6C

P921

Q36669451-ADA16CD9-9E66-4C84-94A4-69B70384FD60

P932

Q36669451-A17FD4C4-D612-45B1-AAB6-4CC52D08B772

P356

AAC.48.8.2951-2957.2004

P1433

Antimicrobial Agents and Chemotherapy

P1476

Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis

@en

P2093

B L Suresh

http://www.w3.org/2001/XMLSchema#string

B N Mahesh

http://www.w3.org/2001/XMLSchema#string

E Kantharaj

http://www.w3.org/2001/XMLSchema#string

Parvinder Kaur

http://www.w3.org/2001/XMLSchema#string

R Jayashree

http://www.w3.org/2001/XMLSchema#string

Radha K Shandil

http://www.w3.org/2001/XMLSchema#string

Ramesh Jayaram

http://www.w3.org/2001/XMLSchema#string

Sheshagiri Gaonkar

http://www.w3.org/2001/XMLSchema#string

Sowmya Bharath

http://www.w3.org/2001/XMLSchema#string

V Balasubramanian

http://www.w3.org/2001/XMLSchema#string

P2860

Role of individual drugs in the chemotherapy of tuberculosis

Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model

Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis

Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis

Does the dose matter?

Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages

Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.

Basic mechanisms of chemotherapy.

Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.

P304

2951-2957

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.48.8.2951-2957.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15273105

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

P932

478500

http://www.w3.org/2001/XMLSchema#string